Archive for the ‘Hospital Clínic’ Category

Friday February 8th, 2013

Dr. Jordi Bruix leads a document that establishes radiological diagnostic criteria for hepatocellular carcinoma in the US

The American Society of Radiology publishes in its journal Radiology an updated article summarizing the new recommendations to diagnose and follow patients with hepatocellular carcinoma considered for liver transplantation in the United States. The document is the result of a task force created in 2008 in the heart of an expert conference organized by UNOS (the american organ distribution agency). Dr. Jordi Bruix, head of the Hepatic Oncology IDIBAPS – Hospital Clínic research team, participated as an international expert in the field of diagnosis and treatment of liver cancer. He is the last author of this document that defines the strategy in the US, which includes other internationally renowned experts from institutions such as Tufts University Medical School, Carolinas Medical Center, Mayo Clinic and University of Michigan Hospital.

Read the rest of this entry »

Comments Closed
Thursday January 24th, 2013

New Key players against Rare Diseases presented at the F.C. Barcelona’s stadium

A multi-million Euro initiative is bringing together researchers from across the world to develop new diagnostic tools and new treatments for people with rare diseases and to connect research data in this area on a global scale. Rare diseases – while individually uncommon – affect one person in every 17 and 80% have a genetic component. Today, the EU has announced 38 million Euro funding for research towards new treatments and for the development of a central global rare disease hub involving 70 institutions that will allow scientists to share data from their genomics research projects. Dr. Joan Lluis Vives-Corrons, a physician from IDIBAPS-Hospital Clínic and coordinator of ENERCA, is an associated partner of one of those projects.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Wednesday January 23rd, 2013

The UPC and the Hospital Clínic de Barcelona create a device for rehabilitating the pelvic floor at home

A team of researchers at the Biomedical Engineering Research Centre (CREB) of the UniversitatPolitècnica de Catalunya – BarcelonaTech (UPC) and the Pelvic Floor Unit of the Hospital Clínicde Barcelona have developed a high-performance device for rehabilitating the pelvic floor at home. The device offersadvanced features, similar to those used in clinical practice.

Exercises to rehabilitate the pelvic floor are recommended as the initial treatment for urinary incontinence, a problem affecting more than 81 million people worldwide, most of them women. In Spain 15% of women in the general population and 25% of women aged 65 years and over suffer from this complaint. Performing voluntary contractions of the pelvic floor muscles requires training to ensure that the right muscles are activated and that the contraction is performed correctly.If the patient forces the muscles of the abdomen, the problem may be aggravated.

Read the rest of this entry »

Comments Closed
Thursday January 17th, 2013

Early treatment for HIV slows damage to immune system and reduces risk of transmission

A 48-week course of antiretroviral medication taken in the early stages of HIV infection slows the damage to the immune system and delays the need for long term treatment, according to research published yesterday in the New England Journal of Medicine. However, the delay was only marginally longer than the time already spent on treatment. The study, the largest clinical trial ever undertaken looking at treating people with recent HIV infection, also suggests that the treatment lowers the amount of virus in the blood for up to sixty weeks after it is stopped, which potentially reduces the risk of onward transmission. The only Spanish participant was the HIV Unit of the Infectious Disease Service from IDIBAPS – Hospital Clínic of Barcelona, lead by Dr. Josep Maria Gatell. Dr. Josep Maria Miró was the Principal Investigator of the team, participated in the study design, the inclusion of participants and is member of the Steering Committee of the SPARTAC trial. Dr. JM Miró is one of the main authors of the article published in New England Journal of Medicine this week.

Read the rest of this entry »

Comments Closed
Monday January 14th, 2013

Acute cough alone should not be a guide symptom for antibiotic prescription

Acute uncomplicated lower-respiratory-tract infection, understood as cough of no more than 28 days’ duration, is the most common acute illness managed in primary care in developed countries. Even in low-antibiotic-prescribing countries, most patients with these symptoms will receive antibiotics. Although consensus opinion has been to restrict antibiotic use in such infections, the debate about the balance of benefit and harm continues. The Lancet Infectious Diseases has published an article led by the GRACE consortium addressing this problem. The work, involving over 2.000 patients in 12 countries, concludes that amoxicillin provides little benefit for acute lower respiratory-tract infection in primary care, when pneumonia is not suspected clinically. One of the authors of the article is Dr. Antoni Torres, full Professor at the University of Barcelona faculty of Medicine and leader of the IDIBAPS team Applied research in infectious respiratory diseases, critically ill patients and lung cancer. He coordinated, together with Dr. Núria Sánchez and the nurse Patricia Fernández, the tasks developed by the professionals at Casanova Primary Care Center (CAP Casanova, Barcelona).

Information via: www.idibapsrespiratoryresearch.org

Comments Closed
Wednesday January 2nd, 2013

A therapeutic dendritic cell vaccine for HIV-1 infection controls virus replication temporarily

Combination antiretroviral therapy (cART) is a success of modern medicine that greatly improves survival and quality of life of HIV-1–infected patients. The major drawback is that cART must be maintained indefinitely causing inconveniences to patients, potential long term toxicities and carrying elevated economical cost. Research teams across the globe work to find an alternative to “cART for life”, such as inducing HIV-1–specific immune responses to control viral replication after discontinuation of cART. Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS at University of Barcelona, led by Dr. Josep Maria Gatell, report today in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new therapeutic vaccine candidate.


Watch it on Youtube in English.

Read the rest of this entry »

Comments Closed
 Page 15 of 35  « First  ... « 13  14  15  16  17 » ...  Last »